Misplaced Pages

Draft:GenBio AI: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactivelyContent deleted Content addedVisualWikitext
Revision as of 18:15, 19 December 2024 editRobiriondo (talk | contribs)18 edits Added startup founded by world-renowned researcher Eric Xing.  Latest revision as of 06:16, 28 December 2024 edit undoCitation bot (talk | contribs)Bots5,427,331 edits Altered title. Added date. | Use this bot. Report bugs. | Suggested by BorgQueen | Linked from User:AlexNewArtBot/PhysicsSearchResult | #UCB_webform_linked 277/351 
(6 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{AFC submission|d|corp|u=Robiriondo|ns=118|decliner=WeirdNAnnoyed|declinets=20241219214956|ts=20241219200019}} <!-- Do not remove this line! -->
⚫ {{Short description|Global biotechnology and artificial intelligence company}}

{{AFC comment|1=The subject does not appear to be notable by the guidelines of ]. All sources cited are press releases, the company's own material, or LinkedIn or other unreliable self-published sources. We need significant coverage in more than one reliable, independent source to have an article. ] (]) 21:49, 19 December 2024 (UTC)}}

----

⚫ {{Short description|Global biotechnology and artificial intelligence company founded by world-renowned researchers.}}
{{Draft topics|stem}}
{{AfC topic|org}}

{{Draft article}}
{{Infobox company {{Infobox company
| name = GenBio.AI, Inc. | name = GenBio.AI, Inc.
Line 5: Line 15:
| industry = {{ubl|]|]}} | industry = {{ubl|]|]}}
| foundation = {{Start date and age|2024}} | foundation = {{Start date and age|2024}}
| founders = {{unbulleted list|Eric Xing|Le Song}} | founders = {{unbulleted list|]|Le Song}}
| key_people = {{unbulleted list|Eric Xing (Chief Scientist)|Le Song (CTO)}} | key_people = {{unbulleted list|Eric Xing (Chief Scientist)|Le Song (CTO)}}
| location_city = {{ubl|]|]|]}} | location_city = {{ubl|]|]|]}}
| homepage = {{url|https://genbio.ai/}} | homepage = {{url|https://genbio.ai/}}
}} }}


'''GenBio AI''' (legal name: '''GenBio.AI, Inc.''') is a biotechnology and artificial intelligence company headquartered in ], with satellite offices in ] and ]. The company focuses on the development of the world’s first AI-Driven Digital Organism (AIDO), an integrated system of multiscale foundation models designed to simulate, program, and predict biological outcomes at various scales, including DNA, RNA, proteins, cells, and evolutionary data. '''GenBio AI''' (legal name: '''GenBio.AI, Inc.'''<ref>{{cite web |title=GenBio AI Legal Name |url=https://genbio.ai/privacy-policy/ |website=GenBio AI|date=27 January 2021 }}</ref>) is a biotechnology and artificial intelligence company headquartered in ], with satellite offices in ] and ]. The company focuses on the development of the world’s first AI-Driven Digital Organism (AIDO), an integrated system of multiscale foundation models designed to simulate, program, and predict biological outcomes at various scales, including DNA, RNA, proteins, cells, and evolutionary data. <ref>{{cite news |title=GenBio AI Releases Phase 1 of World's First Digital Organism to Transform Medical Research |url=https://finance.yahoo.com/news/genbio-ai-releases-phase-1-120000138.html |publisher=Yahoo Finance}}</ref><ref>{{cite news |title=GenBio AI Releases Phase 1 of World's First Digital Organism to Transform Medical Research |url=https://apnews.com/press-release/pr-newswire/medical-technology-medical-research-fabian-theis-eran-segal-biology-3d340fa9bffd1bf0cb896a0cbea9cd41 |publisher=Associated Press |date=19 December 2024}}</ref><ref>{{cite news |title=GenBio AI Releases Phase 1 of World's First Digital Organism to Transform Medical Research |url=https://www.biospace.com/press-releases/genbio-ai-releases-phase-1-of-worlds-first-digital-organism-to-transform-medical-research |publisher=BioSpace |date=19 December 2024}}</ref>


== History == == History ==
GenBio AI was founded in 2024 by Eric Xing and Le Song, prominent researchers in ] and ]. The company’s launch coincided with the presentation of six peer-reviewed technical papers at the ] (NeurIPS) detailing the technical framework behind AIDO. GenBio AI was founded in 2024 by ] and Le Song, prominent researchers in ] and ]. The company’s launch coincided with the presentation of six peer-reviewed technical papers at the ] (NeurIPS)<ref>{{cite web |title=AI for New Drug Modalities |url=https://sites.google.com/view/newmodality-aidrug |website=AIDrugX at NeurIPS 2024}}</ref> detailing the technical framework behind AIDO. <ref>{{cite web |title=GenBio AI - Published Research at NeurIPS 2024 |url=https://genbio.ai/#:~:text=OUR%20WORK-,Research,-%23 |website=GenBio AI}}</ref>


== Technology == == Technology ==
GenBio AI’s flagship technology is the AI-Driven Digital Organism (AIDO), which integrates six foundational models that span multiple levels of biological complexity: GenBio AI’s flagship technology is the AI-Driven Digital Organism (AIDO), which integrates six foundational models that span multiple levels of biological complexity:


* '''AIDO-DNA''': A 7-billion-parameter model trained on genomic data from 796 species, designed for genomic function and structure analysis. * '''AIDO-DNA''': A 7-billion-parameter model trained on genomic data from 796 species, designed for genomic function and structure analysis.<ref>{{cite journal |title=Toward AI-Driven Digital Organism: A System of Multiscale Foundation Models for Predicting, Simulating and Programming Biology at All Levels |journal=arXiv |date=9 December 2024 |url=https://arxiv.org/html/2412.06993v1}}</ref>
* '''AIDO-RNA''': A 1.6-billion-parameter model focused on RNA structure prediction, genetic regulation, and vaccine development. * '''AIDO-RNA''': A 1.6-billion-parameter model focused on RNA structure prediction, genetic regulation, and vaccine development.
* '''AIDO-Protein''': A computationally efficient model for studying protein functions and interactions. * '''AIDO-Protein''': A computationally efficient model for studying protein functions and interactions.
Line 26: Line 36:
* '''Evolutionary Information Model''': Providing insights into molecular evolution. * '''Evolutionary Information Model''': Providing insights into molecular evolution.


The models are interoperable, enabling a unified platform for simulating and programming biological processes across molecular, cellular, and systemic levels. AIDO is noted for its multitasking efficiency, capable of solving up to 300 tasks simultaneously. The models are interoperable, enabling a unified platform for simulating and programming biological processes across molecular, cellular, and systemic levels. AIDO is noted for its multitasking efficiency, capable of solving up to 300 tasks simultaneously.<ref>{{cite web |title=GenBio AI - Published Research at NeurIPS 2024 |url=https://genbio.ai/#:~:text=OUR%20WORK-,Research,-%23 |website=GenBio AI}}</ref>


== Applications == == Applications ==
Line 39: Line 49:


== Leadership == == Leadership ==
* '''Eric Xing''': Co-founder and Chief Scientist, a pioneer in ] and ]. * ''']''': Co-founder and Chief Scientist, a pioneer in ] and ].<ref>{{cite web |last1=Xing |first1=Eric |title=Professor Eric Xing announces GenBio AI to the public on LinkedIn |url=https://www.linkedin.com/posts/eric-xing-b34a0b_home-activity-7275537963453722626-dxs2?utm_source=share&utm_medium=member_desktop |website=LinkedIn}}</ref>
* '''Le Song''': Co-founder and Chief Technology Officer, specializing in AI applications in biological systems. * '''Le Song''': Co-founder and Chief Technology Officer, specializing in AI applications in biological systems.


The advisory board includes prominent scientists such as: The advisory board includes prominent scientists such as:
* '''Eran Segal''': Department of Computer Science, ]. * ''']''': Department of Computer Science, ].
* '''Fabian Theis''': Director of the Institute for Computational Biology at ]. * '''Fabian Theis''': Director of the Institute for Computational Biology at ].


== Global Presence == == Global Presence ==
GenBio AI operates globally with its headquarters in ], and additional labs in ] and ]. The team includes experts from institutions such as ], ], ], and the ]. GenBio AI operates globally with its headquarters in ], and additional labs in ] and ]. The team includes experts from institutions such as ], ], ], and the ].<ref>{{cite web |title=Global Offices, GenBio AI |url=https://genbio.ai/#:~:text=Silicon%20Valley%20%7C%20Paris%20%7C%20Abu%20Dhabi |website=GenBio AI}}</ref>


== External Links == == External Links ==
Line 59: Line 69:


== References == == References ==
⚫ <references />
1. GenBio AI. (2024). .


{{Draft categories|
2. Toward AI-Driven Digital Organism: A System of Multiscale Foundation Models for Predicting, Simulating, and Programming Biology at All Levels. Retrieved from .
⚫ ]

⚫ ]
3. Accurate and General DNA Representations Emerge from Genome Foundation Models at Scale. Retrieved from .
⚫ ]

⚫ ]
4. A Large-Scale Foundation Model for RNA Function and Structure Prediction. Retrieved from .
⚫ ]

}}
5. Mixture of Experts Enable Efficient and Effective Protein Understanding and Design. Retrieved from .

6. Scaling Dense Representations for Single Cell with Transcriptome-Scale Context. Retrieved from .

7. Balancing Locality and Reconstruction in Protein Structure Tokenizer. Retrieved from .

8. Retrieval Augmented Protein Language Models for Protein Structure Prediction. Retrieved from .
⚫ <references />


{{Drafts moved from mainspace|date=December 2024}}
⚫ ]
⚫ ]
⚫ ]
⚫ ]
⚫ ]

Latest revision as of 06:16, 28 December 2024

Submission declined on 19 December 2024 by WeirdNAnnoyed (talk).This draft's references do not show that the subject qualifies for a Misplaced Pages article. In summary, the draft needs multiple published sources that are:
Make sure you add references that meet all four of these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Misplaced Pages.
  • If you would like to continue working on the submission, click on the "Edit" tab at the top of the window.
  • If you have not resolved the issues listed above, your draft will be declined again and potentially deleted.
  • If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors.
  • Please do not remove reviewer comments or this notice until the submission is accepted.
Where to get help
  • If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews.
  • If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed.
How to improve a draft

You can also browse Misplaced Pages:Featured articles and Misplaced Pages:Good articles to find examples of Misplaced Pages's best writing on topics similar to your proposed article.

Improving your odds of a speedy review

To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags.

Add tags to your draft Editor resources Declined by WeirdNAnnoyed 12 days ago. Last edited by Citation bot 4 days ago. Reviewer: Inform author.
ResubmitPlease note that if the issues are not fixed, the draft will be declined again.
  • Comment: The subject does not appear to be notable by the guidelines of WP:NCORP. All sources cited are press releases, the company's own material, or LinkedIn or other unreliable self-published sources. We need significant coverage in more than one reliable, independent source to have an article. WeirdNAnnoyed (talk) 21:49, 19 December 2024 (UTC)
Global biotechnology and artificial intelligence company founded by world-renowned researchers.
This is a draft article. It is a work in progress open to editing by anyone. Please ensure core content policies are met before publishing it as a live Misplaced Pages article.

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL
Easy tools: Citation bot (help) | Advanced: Fix bare URLs · Article logs · Draft logs.

Last edited by Citation bot (talk | contribs) 4 days ago. (Update) Finished drafting? Submit for review or Publish now
GenBio.AI, Inc.
Company typePrivate
Industry
Founded2024; 1 year ago (2024)
Founders
Headquarters
Key people
  • Eric Xing (Chief Scientist)
  • Le Song (CTO)
Websitegenbio.ai

GenBio AI (legal name: GenBio.AI, Inc.) is a biotechnology and artificial intelligence company headquartered in Palo Alto, California, with satellite offices in Paris and Abu Dhabi. The company focuses on the development of the world’s first AI-Driven Digital Organism (AIDO), an integrated system of multiscale foundation models designed to simulate, program, and predict biological outcomes at various scales, including DNA, RNA, proteins, cells, and evolutionary data.

History

GenBio AI was founded in 2024 by Eric Xing and Le Song, prominent researchers in machine learning and computational biology. The company’s launch coincided with the presentation of six peer-reviewed technical papers at the Conference on Neural Information Processing Systems (NeurIPS) detailing the technical framework behind AIDO.

Technology

GenBio AI’s flagship technology is the AI-Driven Digital Organism (AIDO), which integrates six foundational models that span multiple levels of biological complexity:

  • AIDO-DNA: A 7-billion-parameter model trained on genomic data from 796 species, designed for genomic function and structure analysis.
  • AIDO-RNA: A 1.6-billion-parameter model focused on RNA structure prediction, genetic regulation, and vaccine development.
  • AIDO-Protein: A computationally efficient model for studying protein functions and interactions.
  • AIDO-Single Cell: Pre-trained on a dataset of 50 million human cells, capable of analyzing entire transcriptomes.
  • Protein Structure Model: Specializing in three-dimensional modeling of protein folding and structure-function relationships.
  • Evolutionary Information Model: Providing insights into molecular evolution.

The models are interoperable, enabling a unified platform for simulating and programming biological processes across molecular, cellular, and systemic levels. AIDO is noted for its multitasking efficiency, capable of solving up to 300 tasks simultaneously.

Applications

GenBio AI’s technology addresses critical challenges in medicine and biotechnology:

  • Drug Discovery: AIDO accelerates the identification of potential therapeutics by simulating millions of compounds and predicting their biological effects.
  • Personalized Medicine: The platform supports the creation of digital patient twins to design customized treatment plans and reduce adverse drug reactions.
  • Disease Understanding: AIDO provides tools to study systemic interactions, enabling researchers to explore conditions such as cancer and neurodegenerative diseases.

Research Contributions

The company has published six technical papers outlining the methodologies behind AIDO. These include advancements in sparse transformers, retrieval-augmented learning, and large-scale biological data integration. The research establishes AIDO as a new standard in biological modeling.

Leadership

  • Eric Xing: Co-founder and Chief Scientist, a pioneer in AI and computational biology.
  • Le Song: Co-founder and Chief Technology Officer, specializing in AI applications in biological systems.

The advisory board includes prominent scientists such as:

Global Presence

GenBio AI operates globally with its headquarters in Palo Alto, and additional labs in Paris and Abu Dhabi. The team includes experts from institutions such as Carnegie Mellon University, Stanford University, MBZUAI, and the Weizmann Institute of Science.

External Links

See also

References

  1. "GenBio AI Legal Name". GenBio AI. 27 January 2021.
  2. "GenBio AI Releases Phase 1 of World's First Digital Organism to Transform Medical Research". Yahoo Finance.
  3. "GenBio AI Releases Phase 1 of World's First Digital Organism to Transform Medical Research". Associated Press. 19 December 2024.
  4. "GenBio AI Releases Phase 1 of World's First Digital Organism to Transform Medical Research". BioSpace. 19 December 2024.
  5. "AI for New Drug Modalities". AIDrugX at NeurIPS 2024.
  6. "GenBio AI - Published Research at NeurIPS 2024". GenBio AI.
  7. "Toward AI-Driven Digital Organism: A System of Multiscale Foundation Models for Predicting, Simulating and Programming Biology at All Levels". arXiv. 9 December 2024.
  8. "GenBio AI - Published Research at NeurIPS 2024". GenBio AI.
  9. Xing, Eric. "Professor Eric Xing announces GenBio AI to the public on LinkedIn". LinkedIn.
  10. "Global Offices, GenBio AI". GenBio AI.
This page will be placed in the following categories if it is moved to the article namespace.Categories:

Categories: